Canada Life’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$61.1M Buy
78,886
+3,668
+5% +$2.81M 0.11% 159
2025
Q4
$58.1M Sell
75,218
-15,786
-17% -$10.7M 0.1% 165
2025
Q3
$51M Buy
91,004
+3,910
+4% +$2.21M 0.07% 240
2025
Q2
$45.8M Sell
87,094
-37,529
-30% -$20.9M 0.07% 242
2025
Q1
$79.1M Buy
124,623
+3,758
+3% +$2.58M 0.14% 135
2024
Q4
$86M Sell
120,865
-5,331
-4% -$4.47M 0.15% 122
2024
Q3
$133M Buy
126,196
+6,105
+5% +$6.79M 0.23% 78
2024
Q2
$126M Buy
120,091
+18,927
+19% +$18.3M 0.24% 77
2024
Q1
$97.4M Sell
101,164
-10,824
-10% -$10.3M 0.2% 105
2023
Q4
$97.8M Sell
111,988
-11,375
-9% -$9.37M 0.21% 91
2023
Q3
$101M Sell
123,363
-236
-0.2% -$185K 0.24% 80
2023
Q2
$89.3M Sell
123,599
-8,241
-6% -$6.35M 0.21% 95
2023
Q1
$108M Sell
131,840
-12,386
-9% -$9.34M 0.27% 70
2022
Q4
$105M Sell
144,226
-24,961
-15% -$18.4M 0.28% 72
2022
Q3
$116M Sell
169,187
-7,467
-4% -$4.7M 0.33% 61
2022
Q2
$105M Buy
176,654
+4,377
+3% +$2.85M 0.28% 67
2022
Q1
$127M Sell
172,277
-1,637
-0.9% -$1.04M 0.26% 73
2021
Q4
$110M Buy
173,914
+16,481
+10% +$10.1M 0.23% 82
2021
Q3
$95.8M Buy
157,433
+4,654
+3% +$2.89M 0.22% 85
2021
Q2
$85.3M Sell
152,779
-24,151
-14% -$12.2M 0.19% 102
2021
Q1
$83.3M Sell
176,930
-12,222
-6% -$5.95M 0.2% 103
2020
Q4
$91.2M Buy
189,152
+40,758
+27% +$22M 0.17% 127
2020
Q3
$83M Buy
148,394
+18,273
+14% +$11.1M 0.18% 128
2020
Q2
$80.7M Buy
130,121
+65,976
+103% +$37.4M 0.19% 125
2020
Q1
$31.5M Sell
64,145
-16,507
-20% -$6.81M 0.08% 237
2019
Q4
$30.1M Buy
80,652
+3,579
+5% +$1.2M 0.07% 306
2019
Q3
$21.4M Sell
77,073
-7,237
-9% -$2.14M 0.05% 366
2019
Q2
$26.4M Buy
84,310
+388
+0.5% +$129K 0.06% 322
2019
Q1
$34.4M Buy
83,922
+17,957
+27% +$7.39M 0.09% 224
2018
Q4
$23.8M Buy
65,965
+16,865
+34% +$6.17M 0.07% 275
2018
Q3
$19.9M Sell
49,100
-7,559
-13% -$2.88M 0.05% 346
2018
Q2
$19.5M Buy
56,659
+924
+2% +$289K 0.05% 356
2018
Q1
$19.2M Sell
55,735
-15,436
-22% -$5.37M 0.05% 355
2017
Q4
$26.7M Buy
71,171
+4,635
+7% +$1.88M 0.06% 289
2017
Q3
$29M Buy
66,536
+11,529
+21% +$5.49M 0.07% 276
2017
Q2
$27M Sell
55,007
-134
-0.2% -$58.6K 0.07% 280
2017
Q1
$21.3M Buy
55,141
+458
+0.8% +$170K 0.06% 321
2016
Q4
$20.1M Sell
54,683
-854
-2% -$325K 0.06% 317
2016
Q3
$22.3M Buy
55,537
+1,410
+3% +$566K 0.07% 295
2016
Q2
$18.9M Buy
54,127
+13,020
+32% +$5.01M 0.06% 326
2016
Q1
$14.8M Sell
41,107
-8,397
-17% -$3.46M 0.05% 323
2015
Q4
$26.9M Buy
49,504
+8,142
+20% +$4.41M 0.1% 216
2015
Q3
$19.2M Sell
41,362
-50,988
-55% -$27.4M 0.08% 263
2015
Q2
$47.1M Sell
92,350
-314
-0.3% -$153K 0.16% 142
2015
Q1
$41.7M Sell
92,664
-3,037
-3% -$1.29M 0.14% 165
2014
Q4
$39.3M Buy
95,701
+17,473
+22% +$6.87M 0.13% 180
2014
Q3
$28.2M Buy
78,228
+41,085
+111% +$13.8M 0.09% 230
2014
Q2
$10.5M Sell
37,143
-279
-0.7% -$82.7K 0.03% 415
2014
Q1
$11.2M Buy
37,422
+1,108
+3% +$341K 0.04% 396
2013
Q4
$10M Buy
36,314
+36,019
+12,210% +$10.4M 0.04% 413
2013
Q3
$92K Sell
295
-17
-5% -$4.47K ﹤0.01% 986
2013
Q2
$70K Buy
+312
New +$72.7K ﹤0.01% 648

Other funds holding REGN

Canada Life's REGN Position: Q1 2026 in Review

Canada Life increased its Regeneron Pharmaceuticals (REGN) stake by 4.9% in Q1 2026, buying an estimated $2.81M and bringing the position to 78,886 shares worth $61.1M. The position accounts for 0.11% of the portfolio, ranked #159.

Canada Life first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $133M in Q3 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Canada Life held 78,886 shares of Regeneron Pharmaceuticals worth $61.1M as of Q1 2026.
  • Canada Life bought 3,668 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $2.81M.
  • Regeneron Pharmaceuticals made up 0.11% of Canada Life's portfolio in Q1 2026, its #159 holding.
  • Canada Life first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Canada Life's Regeneron Pharmaceuticals position peaked at $133M in Q3 2024.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Canada Life's 13F filing for Q1 2026, filed 14 May 2026.